Pharma BD Deal Intelligence
A merger that scaled up but never lasted: Invitrogen's $6.7B all-cash-and-stock deal for Applied Biosystems formed Life Technologies, combining ~$3.5B in revenue and 9,500 employees to challenge Illumina and Roche/454. The SOLiD sequencing platform lost the sequencing race, and the combined company itself was sold to Thermo Fisher for $13.6B just over five years later.
Merger created a scaled life-sciences leader (Life Technologies) that grew steadily, but its flagship sequencing asset (SOLiD) lost the platform war to Illumina, and the combined company itself was sold off to Thermo Fisher just over five years later.
Full analysis, sources & comparables →Robert W. Baird analyst Quintin Lai said the Invitrogen-AB combination occupies the genetics and molecular-biology space 'where Thermo Fisher is least exposed'…
The Invitrogen-AB merger is taught as a model of complementary-platform M&A in life-science tools — the asset base later attracted Thermo Fisher's $13.6B…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Invitrogen acquired Applied Biosystems in a cash-and-stock transaction at $38 per share, forming Life Technologies with approximately $3.5 billion in combined revenues, 9,500 employees, and operations in over 100 countries. Analysts noted the deal combined largely non-overlapping genetics and molecular-biology franchises -- Applied Biosystems' instruments (including the SOLiD next-gen sequencing platform) with Invitrogen's reagents -- positioning the combined company against Illumina and Roche/454; Life Technologies was itself acquired by Thermo Fisher for $13.6 billion five years later.
Merger created a scaled life-sciences leader (Life Technologies) that grew steadily, but its flagship sequencing asset (SOLiD) lost the platform war to Illumina, and the combined company itself was sold off to Thermo Fisher just over five years later.
Assessment window: 15yr post-close.
$3.5B Combined Invitrogen+AB pro-forma annual revenue at deal (~$3.5B)
This is a life-sciences-tools transaction, not a disease-specific deal. Invitrogen supplied molecular biology reagents (cell culture media, transfection reagents, antibodies, GIBCO/Molecular Probes brands). Applied Biosystems supplied capital equipment — Sanger sequencers, qPCR systems (TaqMan, 7500/7900HT), mass spectrometers, and the SOLiD next-generation sequencing platform. Combined, the new Life Technologies positioned itself as a one-stop research-tools vendor across genomics, proteomics, cell biology, and applied markets (forensics, food safety, pharma QC).
At deal close (November 21, 2008), the life-science-tools market was led by Thermo Fisher Scientific (post-2006 Thermo Electron + Fisher merger, ~$10.6B), with Roche Applied Science, Qiagen, Sigma-Aldrich, Bio-Rad, and Agilent as competitors. Robert W. Baird analyst Quintin Lai told GenomeWeb the Invitrogen-AB combination created 'a category killer' in genetics and molecular biology with minimal direct overlap with Thermo Fisher's instruments-and-consumables stack. Scientia Advisors' Harry Glorikian called it 'a very positive move for both entities.' Strategically, the deal married AB's installed base of Sanger 3730xl sequencers and 7500 qPCR systems with Invitrogen's reagent pull-through — a razor/razorblade model. AB's SOLiD next-generation sequencing platform (v3.0 launched October 2008) was positioned to compete with Illumina's Solexa GA-II and Roche/454's GS-FLX in the emerging $10K-genome race. Life Technologies preserved both brand identities (AB for instruments, Invitrogen for reagents). The combined entity later acquired Ion Torrent (2010) for benchtop NGS before itself being acquired by Thermo Fisher for $13.6B in 2014, ultimately creating a single dominant tools platform — vindicating the original consolidation thesis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Invitrogen Corporation / Applied Biosystems Inc. (this deal) | 2008 | $6.7B | 54 |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
← Browse all deals · How we score deals
More: 2008 deals